Riskpilot← Back to searchSign inGet full accessMEDISTIM ASA
ASAActiveOrg 936656013Økernveien 94, 0579 OsloManufacture of instruments and appliances for measuring, testing and navigation · NACE 2651Est. 1984104 employees
Revenue 2024
NOK 354M
+4% vs 2023
EBITDA margin
34.8%
+2% vs 2023
Equity ratio
44.8%
Financial strength
Net profit 2024
NOK 103,3M
+4% vs 2023
| Revenue | NOK 354M | +4% |
| EBITDA | NOK 123,3M | +2% |
| Net profit | NOK 103,3M | +4% |
| Total assets | NOK 466,7M | +16% |
| Equity | NOK 209,2M | -3% |
| Employees | 104 | — |
Legal name
MEDISTIM ASA
Org number
936656013
Legal form
Allmennaksjeselskap
NACE code
2651 · Manufacture of instruments and appliances for measuring, testing and navigation
Founded
10. juni 1984
Share capital
NOK 4 584 334
Employees
104 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Drive forskning, utvikling, produksjon, distribusjon og salg av medisinsk utstyr gjennom egen virksomhet eller i form av deltakelse i andre selskaper, samt det som hermed står i forbindelse.
Address
Økernveien 94, 0579 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 90 349 | 105 236 | 122 077 | 130 462 | 154 330 | 171 146 | 200 503 | 195 444 | 258 518 | 308 645 | 341 024 | 354 048 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −28 183 | −33 310 | −35 988 | −41 692 | −48 240 | −54 792 | −63 520 | −62 858 | −73 536 | −80 239 | −89 360 | −94 780 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 30 130 | 32 430 | 40 733 | 41 907 | 48 901 | 51 392 | 62 498 | 59 369 | 90 995 | 115 581 | 120 624 | 123 317 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −6 820 | −7 179 | −9 327 | −10 842 | −12 019 | −11 243 | −10 963 | −13 961 | −13 715 | −13 888 | −12 599 | −13 023 |
| EBIT | 0 | 0 | 0 | 0 | 0 | 0 | 23 310 | 25 251 | 31 406 | 31 065 | 36 882 | 40 149 | 51 535 | 45 408 | 77 280 | 101 693 | 108 025 | 110 294 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 8 908 | 6 191 | 10 325 | 17 612 | 10 933 | 15 507 | 18 651 | 24 631 | 20 083 | 27 756 | 16 662 | 16 257 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 32 218 | 31 442 | 41 731 | 48 677 | 47 815 | 55 656 | 70 186 | 70 039 | 97 363 | 129 449 | 124 687 | 126 551 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | 7 418 | 7 762 | 10 161 | 6 961 | 9 395 | 9 513 | 11 858 | 9 864 | 16 682 | 21 342 | 25 233 | 23 240 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 24 800 | 23 680 | 31 570 | 41 716 | 38 420 | 46 143 | 58 328 | 60 175 | 80 681 | 108 107 | 99 454 | 103 311 |
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | — | — | — | — | — | 148 653 | 168 612 | 182 667 | 175 022 | 197 109 | 206 163 | 233 132 | 243 720 | 310 447 | 382 175 | 402 231 | 466 728 |
| Equity | — | — | — | — | — | — | 102 791 | 101 129 | 103 944 | 115 054 | 117 845 | 124 143 | 133 278 | 140 468 | 160 349 | 191 696 | 214 848 | 209 186 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 7 753 | 20 199 | 12 417 | 2 552 | 10 500 | 10 500 | 4 500 | 12 162 | 35 278 | 39 429 | 40 690 | 79 474 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 38 109 | 47 283 | 66 306 | 57 416 | 68 765 | 71 521 | 95 353 | 91 088 | 114 820 | 151 050 | 146 693 | 178 070 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 45 862 | 67 482 | 78 723 | 59 968 | 79 265 | 82 021 | 99 853 | 103 250 | 150 098 | 190 479 | 187 383 | 257 544 |
EBITDA margin
34.8%
This company
15.8%
Market median
+120% vs market
20072024
Equity ratio
44.8%
This company
38.2%
Market median
+17% vs market
20072024
Return on equity
49.4%
This company
18.4%
Market median
+168% vs market
20072024
Net profit margin
29.2%
This company
8.1%
Market median
+260% vs market
20072024
Asset turnover
0.76×
This company
1.12×
Market median
-32% vs market
20072024
Debt / equity
1.23×
This company
0.62×
Market median
-98% vs market
20072024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via Brønnøysundsregistrene · Period 2007-01-01 – 2007-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KE Chief Executive Officer | Chief Executive Officer | 2009 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Deputy Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
State Street Bank And Trust Comp | Company | 15.0% | 15.0% | 2024 |
Skandinaviska Enskilda Banken Ab | Company | 14.4% | 14.4% | 2024 |
Acapital Medi Holdco As | Company | 10.4% | 10.4% | 2024 |
Aeternum Capital As | Company | 10.2% | 10.2% | 2022 |
Fløtemarken As | Company | 7.0% | 7.0% | 2024 |
| Individual | 6.8% | 6.8% | 2022 | |
Verdipapirfond Odin Norden | Company | 6.4% | 6.4% | 2024 |
J.P. Morgan Se | Company | 5.9% | 5.9% | 2024 |
Follum Invest As | Company | 5.3% | 5.3% | 2024 |
| Individual | 5.0% | 5.0% | 2022 | |
| Individual | 4.9% | 4.9% | 2022 | |
The Northern Trust Comp, London Br | Company | 4.0% | 4.0% | 2024 |
Bnp Paribas | Company | 3.8% | 3.8% | 2024 |
Verdipapirfondet Holberg Norge | Company | 3.7% | 3.7% | 2024 |
| Individual | 3.6% | 3.6% | 2022 | |
Odin Small Cap | Company | 3.3% | 3.3% | 2024 |
| Individual | 3.3% | 3.3% | 2022 | |
| Individual | 2.9% | 2.9% | 2022 | |
| Individual | 2.4% | 2.4% | 2022 | |
| Individual | 2.3% | 2.3% | 2022 | |
The Bank Of New York Mellon Sa/Nv | Company | 2.3% | 2.3% | 2024 |
| Individual | 2.3% | 2.3% | 2022 | |
| Individual | 2.2% | 2.2% | 2022 | |
| Individual | 2.1% | 2.1% | 2024 | |
Caceis Bank | Company | 2.0% | 2.0% | 2024 |
| Individual | 1.8% | 1.8% | 2022 | |
| Individual | 1.5% | 1.5% | 2022 | |
| Individual | 1.5% | 1.5% | 2022 | |
| Individual | 1.4% | 1.4% | 2022 | |
Citibank Europe Plc | Company | 1.4% | 1.4% | 2024 |
Mustad Industrier As | Company | 1.4% | 1.4% | 2024 |
| Individual | 1.3% | 1.3% | 2022 | |
| Individual | 1.3% | 1.3% | 2022 | |
| Individual | 1.3% | 1.3% | 2022 | |
| Individual | 1.1% | 1.1% | 2022 | |
| Individual | 1.1% | 1.1% | 2022 | |
Danske Bank A/S | Company | 1.1% | 1.1% | 2024 |
Verdipapirfondet Danske Invest Norge Vekst | Company | 1.0% | 1.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MEDISTIM ASA 
MEDISTIM NORGE ASBoard members of MEDISTIM ASA also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kari Eian Krogstad | Chief Executive Officer | 0 companies |
| Siri Fürst | Board of Directors | 0 companies |
| Lars Rønn | Board of Directors | 0 companies |
| Jon Helge Hoem | Board of Directors | 0 companies |
| Øyvin Anders Brøymer | Chairman | 0 companies |
| Torben Vedel Stahl Jørgensen | Board of Directors | 0 companies |
| Anthea Christina Barranco Arff-Pettersen | Board of Directors | 0 companies |
| Ole Jesper Dahlberg | Board of Directors | 0 companies |
| Gry Dahle | Board of Directors | 0 companies |
| Anna Sofia Ahlberg | Board of Directors | 0 companies |
| Peder Strand | Board of Directors | 0 companies |
| Tove Raanes | Board of Directors | 0 companies |
| Rune Halvorsen | Board of Directors | 0 companies |
| Bjørn Margido Wiggen | Deputy Chairman | 0 companies |